Clinical Trials

161 enrolled 15 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02282358 2024-03-08

Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Phase 1/2 Terminated

7 enrolled 11 charts

Lymphoma, Lymphoma, Follicular, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02429375 2022-05-12

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

7 enrolled 10 charts

Hodgkin Disease, Recurrence

NCT02805660 2021-04-06

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

Phase 1/2 Terminated

83 enrolled 26 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02303262 2019-01-29

SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma

20 enrolled 11 charts

Sarcoma

Leiomyosarcoma

NCT02993991 2017-12-29

PRIMED-001

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02236195 2017-09-01

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

17 enrolled

Genitourinary

Carcinoma, Transitional Cell, Rubinstein-Taybi Syndrome

NCT00358982 2015-07-03

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

51 enrolled

Hodgkin Disease, Recurrence

NCT00324220 2015-07-01

A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia

Phase 1/2 Completed

66 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00359086 2015-07-01

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

74 enrolled

Lymphoma, Recurrence

NCT00372437 2015-07-01

A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine

Phase 1/2 Completed

47 enrolled

Tumor-Agnostic

Neoplasms

NCT00374296 2015-07-01

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

35 enrolled

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00431873 2015-07-01

A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

21 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00543582 2015-07-01

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

23 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00666497 2015-05-08

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

6 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00323934 2015-01-08

Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Phase 1 Completed

42 enrolled

Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms

NCT00324129 2015-01-08

A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes

Phase 1 Completed

29 enrolled

Leukemia, Myelodysplastic Syndromes

NCT00324194 2015-01-08

A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes

Phase 1 Completed

25 enrolled